Physician profile
Thomas M Dagg
NPI 1861985103
$332.71
in general payments reported to CMS, 2019-2025
10 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2023: $65.80 · 2024: $59.07 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.33 | 2019-2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $33.76 | 2024-2025 | |
| Bioventus LLC | $31.06 | 2025 | Durolane |
| Medtronic, INC. | $27.75 | 2025 | Intellis Adaptivestim |
| Amgen INC. | $27.26 | 2023-2025 | Evenity, Prolia, Otezla |
| Grifols USA, LLC | $22.02 | 2023 | Prolastin-C Liquid |
| Insulet Corporation | $16.94 | 2025 | Omnipod |
| Ferring Pharmaceuticals INC. | $16.51 | 2024 | Euflexxa |
| Sumitomo Pharma America, INC. | $13.93 | 2024 | Gemtesa |
| Abbvie INC. | $13.15 | 2023 | Ubrelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dagg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.